MedTrace Logo

Pregabalin Trial In HIV Neuropathic Pain

NCT01145417 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 217

Last updated 2021-01-28

Study results available
· View outcomes & findings →

Summary

This study examines the safety of pregabalin over a 6 month period in patients with neuropathic pain associated with HIV infection as an extension of another trial that tests the efficacy of pregabalin.

Conditions

  • HIV-1 Infection
  • Neuropathic Pain

Interventions

DRUG

pregabalin (Lyrica)

150 mg-600 mg/day (twice daily)

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States
  • Colombia
  • India
  • Peru
  • Puerto Rico
  • South Africa
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01145417 on ClinicalTrials.gov